Abstract: Anti-CCL8 antibodies and antigen binding fragments thereof are described. Antibodies and fragments thereof can be used for prevention of migration of breast cancer cells. Methods include delivery of an anti-CCL8 antibody or an antigen binding fragment thereof to an area including the breast cancer cells, e.g., delivery to a subject in need thereof in an effective amount.
Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
July 21, 2020
Assignees:
BioNTech AG, Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologic an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gemcinnützige GmbH
Inventors:
Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
Type:
Grant
Filed:
August 3, 2016
Date of Patent:
June 16, 2020
Assignee:
EngMab Sàrl
Inventors:
Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
Type:
Grant
Filed:
July 11, 2014
Date of Patent:
June 16, 2020
Assignee:
THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Feng Wang, Yong Zhang, Yan Liu, Peter G. Schultz
Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
June 2, 2020
Assignee:
CYTOMX THERAPEUTICS, INC.
Inventors:
James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
Abstract: The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N-terminus, and are codon-optimized to increase antibody production in mammalian cells.
Type:
Grant
Filed:
July 21, 2016
Date of Patent:
May 26, 2020
Inventors:
Ilya Vladimirovich Dukhovlinov, Anton Iosifovich Orlov, Mark Borisovich Balazovskiy
Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
May 19, 2020
Assignee:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventors:
Simeon Cua, Andre Boon Hwa Choo, Heng Liang Tan, Wey Jia Fong, Vanessa Mei Yee Ding, Leonard Wen Yan Leong
Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
May 19, 2020
Assignee:
Y-BIOLOGICS INC.
Inventors:
Seil Jang, Bum-Chan Park, Young Woo Park
Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
May 5, 2020
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
May 5, 2020
Assignee:
Y-BIOLOGICS INC.
Inventors:
Seil Jang, Bum-Chan Park, Young Woo Park
Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
April 28, 2020
Assignee:
Y-BIOLOGICS INC.
Inventors:
Seil Jang, Bum-Chan Park, Young Woo Park
Abstract: Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.
Type:
Grant
Filed:
May 28, 2014
Date of Patent:
April 28, 2020
Assignees:
KAOHSIUNG MEDICAL UNIVERSITY, DCB-USA LLC
Inventors:
Tian-Lu Cheng, Chih-Hung Chuang, Hsiu-Fen Ko, Yun-Chi Lu
Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
Abstract: The present disclosure provides methods of treating multiple myeloma in an individual, the methods comprising genotyping an HLA allele and a KIR allele in the individual; and, depending on the outcome of the genotyping, administering a multiple myeloma therapy to the individual. In some embodiments, the multiple myeloma therapy comprises an anti-CD38 antibody, lenalidomide, and dexamethasone. The present disclosure provides methods for selecting a multiple myeloma patient for a multiple myeloma therapy. The present disclosure provides methods for identifying a multiple myeloma patient as likely to experience a beneficial clinical outcome from a multiple myeloma therapy.
Type:
Grant
Filed:
August 4, 2015
Date of Patent:
April 14, 2020
Assignee:
The Regents of the University of California
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Type:
Grant
Filed:
May 25, 2016
Date of Patent:
April 14, 2020
Assignee:
MORPHOSYS AG
Inventors:
Jan Endell, Rainer Boxhammer, Mark Winderlich
Abstract: Disclosed herein are humanized anti-Epidermal Growth Factor (EGF) Receptor antibodies which can inhibit the proliferation of cells expressing the EGF receptor. Humanized anti-EGFR antibodies are capable of binding to the surface of cells and killing the EGF receptor overexpression cells. The invention presents the humanized anti-EGFR antibodies which bind to different epitope and inhibit the tumor formation in a different way than Erbitux. Most importantly, once bound to the surface EGFR, these new anti-EGFR antibodies will internalize rather quickly, which made them ideal candidate for antibody drug conjugation and other biotherapy. The invention also features method of humanization which leads to 90% of the amino acid sequences are human sequence, and significantly reduce the risk of human anti-mouse immunogenicity. The present invention also demonstrated that the humanized anti-EGFR antibodies have the affinity to EGFR in the range of 2.
Abstract: Disclosed are an ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors, and uses thereof in novel tumor resisting drugs. Also disclosed is a new antigen sequence, used for inducing generation of a monoclonal antibody or a polyclonal antibody for the ABCG2. In addition, disclosed is a hybridoma for generating the ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors.